Legal News

Voluntary licensing on the rise as Medicines Patent Pool signs second deal for coronavirus (COVID-19) treatment

Published on: 30 November 2021
Published by: LexisPSL
  • Voluntary licensing on the rise as Medicines Patent Pool signs second deal for coronavirus (COVID-19) treatment

Article summary

Life Sciences analysis: Ellen Lambrix, senior associate at Bristows, discusses Pfizer and Medicines Patent Pool’s (MPP) voluntary licence agreement for PF-07321332, Pfizer’s antiviral treatment for coronavirus (COVID-19). or take a trial to read the full analysis.

Popular documents